Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients - Tang, Bixia; Yan, Xieqiao; Sheng, Xinan; Si, Lu; Cui, Chuanliang; Kong, Yan; Mao, Lili; Lian, Bin; Bai, Xue; Wang, Xuan; Li, Siming; Zhou, Li; et al. (Journal of hematology and oncology, 2019)
Keywords: Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Antitumor agents; Apoptosis; B7-H1 Antigen - metabolism; Biomarkers, Tumor - metabolism; Biopsy; Bladder cancer; Cancer therapies; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - pathology; Care and treatment; CD16 antigen; CD3 antigen; CD8 antigen; CD8-Positive T-Lymphocytes - metabolism; Cell activation; Complications and side effects; Development and progression; Disease control; Dosage and administration; Dose-Response Relationship, Drug; Drug therapy; FDA approval; Female; Follow-Up Studies; Genetic aspects; Genomes; Health aspects; Hematology; Humans; Immunoglobulin G; Immunoglobulin G - administration & dosage; Immunoglobulin G - adverse effects; Immunoglobulin G - therapeutic use; Immunotherapy; Infusions, Intravenous; Intravenous administration; JS001; Kidney cancer; Ligands; Lymphocyte Activation; Lymphocytes; Lymphocytes T; Male; Melanoma; Melanoma - drug therapy; Melanoma - pathology; Metastasis; Middle Aged; Monoclonal antibodies; Monoclonal antibody; Mucosa; Mutation; Oncology; Patients; PD-1; PD-1 protein; PD-L1 protein; Peripheral blood; Programmed Cell Death 1 Receptor - immunology; Progression-Free Survival; Renal cell carcinoma; Safety; Safety and security measures; Skin cancer; Skin Neoplasms - drug therapy; Skin Neoplasms - pathology; T cell receptors; Toxicity; Tumor cells; Urinary tract cancer; Urologic Neoplasms - drug therapy; Urologic Neoplasms - pathology; Urothelial cancer; China; Asia; United States--US; JS001; Urothelial cancer; Monoclonal antibody; Renal cell carcinoma; PD-1; Melanoma